| Trial ID: | L3077 |
| Source ID: | NCT01037582
|
| Associated Drug: |
Nn9924 (Oral)
|
| Title: |
A Two Part Trial Investigating the Safety of NN9924 in Healthy Male Subjects
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2|Healthy
|
| Interventions: |
DRUG: NN9924 (oral)|DRUG: placebo|DRUG: NN9924 (oral)|DRUG: placebo|DRUG: NN9924 (s.c.)|DRUG: NN9924 (i.v.)
|
| Outcome Measures: |
Primary: Number and severity of adverse events (AEs) recorded, from dosing to Day 22 | Secondary: The uptake in blood of oral NN9924 compared to i.v. and s.c. administration of the same compound, from 0 to 504 hours
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
MALE
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
155
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2009-12-17
|
| Completion Date: |
2010-05-07
|
| Results First Posted: |
|
| Last Update Posted: |
2019-01-03
|
| Locations: |
Novo Nordisk Investigational Site, Harrow, HA1 3UJ, United Kingdom
|
| URL: |
https://clinicaltrials.gov/show/NCT01037582
|
